INSMED Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INSMED Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $0 | Feb 23, 2018 |
| FY2017 | Dec 31, 2015 | $0 | Feb 23, 2018 |
| FY2015 | Dec 31, 2013 | $11.50M | Feb 25, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $606.42M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $363.71M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $305.21M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $245.36M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $188.46M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $164.41M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $45.71M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $38.89M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $29.97M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $21.90M | Feb 25, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $37.00M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $32.45M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $25.05M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $17.75M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $7.41M | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Feb 25, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Feb 25, 2020 |
| FY2019 | Mar 31, 2018 | $0 | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $0 | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.28B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($913.77M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($749.57M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($481.53M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($434.65M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($294.09M) | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | ($52.99M) | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | ($60.68M) | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | ($66.51M) | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | ($74.15M) | Feb 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.25B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($878.25M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($709.63M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($457.32M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($375.09M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($265.23M) | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | ($47.08M) | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | ($56.49M) | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | ($62.17M) | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | ($69.51M) | Feb 25, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $771.09M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $598.37M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $571.01M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $397.52M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $272.74M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $181.16M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $131.71M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $145.28M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $109.75M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $122.72M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $701.17M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $461.12M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $344.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $265.78M | Feb 20, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($935.01M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($683.88M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($536.25M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($400.44M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($363.30M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($219.35M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($250.65M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($257.98M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($159.62M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($146.71M) | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.56M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $21.92M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $13.29M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $9.88M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $7.29M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $6.24M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $42.27M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $13.09M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $4.20M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.03B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.33B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.66B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.24B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $796.16M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $742.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $604.56M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $462.05M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $237.96M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.74B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.66B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.57B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $833.04M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $520.27M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $480.63M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $396.29M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $100.99M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $83.47M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $738.98M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $285.38M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($331.92M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $87.95M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $410.47M | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $275.88M | Feb 22, 2024 |
| FY2022 | Dec 31, 2019 | $261.67M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $208.27M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $361.06M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $154.48M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.11M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $136.11M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $136.11M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $136.11M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $136.11M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 17, 2022 |
| FY2011 | Dec 31, 2011 | $0 | Mar 13, 2012 |
| FY2011 | Dec 31, 2010 | $6.29M | Mar 13, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.64B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($4.36B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($3.45B) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($2.70B) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($2.27B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($1.83B) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($1.54B) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.28B) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($957.89M) | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | ($765.24M) | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $510.45M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $555.03M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $482.37M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.07B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $716.78M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $532.76M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $487.43M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $495.07M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $381.17M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $162.59M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $546.77M | Feb 19, 2026 |
| FY2024 | Dec 31, 2024 | $1.12B | Feb 20, 2025 |
| FY2023 | Dec 31, 2023 | $1.18B | Feb 22, 2024 |
| FY2022 | Dec 31, 2022 | $1.15B | Feb 23, 2023 |
| FY2021 | Dec 31, 2021 | $800.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2020 | $450.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $450.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2018 | $450.00M | Feb 22, 2019 |
| FY2017 | Dec 31, 2017 | $55.00M | Feb 23, 2018 |
| FY2016 | Dec 31, 2016 | $55.00M | Feb 23, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 17, 2022 |
| FY2011 | Dec 31, 2011 | (2) | Mar 13, 2012 |
| FY2011 | Dec 31, 2010 | 0 | Mar 13, 2012 |
| FY2011 | Dec 31, 2009 | 9 | Mar 13, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 17, 2022 |
| FY2011 | Dec 31, 2011 | (2) | Mar 13, 2012 |
| FY2011 | Dec 31, 2010 | 0 | Mar 13, 2012 |
| FY2011 | Dec 31, 2009 | 9 | Mar 13, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 214.26M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 179.38M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 147.98M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 135.65M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 118.74M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 102.76M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 89.68M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 77.31M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 76.61M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 62.02M | Feb 23, 2018 |